329 related articles for article (PubMed ID: 30983996)
21. A health economic guide to market access of biosimilars.
Simoens S; Vulto AG
Expert Opin Biol Ther; 2021 Jan; 21(1):9-17. PubMed ID: 33206021
[No Abstract] [Full Text] [Related]
22. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.
Jha A; Upton A; Dunlop WC; Akehurst R
Adv Ther; 2015 Aug; 32(8):742-56. PubMed ID: 26343027
[TBL] [Abstract][Full Text] [Related]
23. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Ahmed I; Kaspar B; Sharma U
Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
[TBL] [Abstract][Full Text] [Related]
24. Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect.
Rezk MF; Pieper B
Rheumatol Ther; 2017 Dec; 4(2):209-218. PubMed ID: 29032452
[TBL] [Abstract][Full Text] [Related]
25. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
Crespi-Lofton J; Skelton JB
J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
[TBL] [Abstract][Full Text] [Related]
26. Biosimilar biological drugs in the treatment of inflammatory bowel diseases.
Kaniewska M; Eder P; Gąsiorowska A; Gonciarz M; Kierkuś J; Małecka-Panas E; Rydzewska G
Prz Gastroenterol; 2019; 14(4):223-227. PubMed ID: 31988667
[TBL] [Abstract][Full Text] [Related]
27. Biosimilar medicines uptake: The role of the clinical pharmacist.
Okoro RN
Explor Res Clin Soc Pharm; 2021 Mar; 1():100008. PubMed ID: 35479506
[TBL] [Abstract][Full Text] [Related]
28. Emerging Role of Biosimilars in Oncology-Hematology in Saudi Arabia: A Practical Perspective.
Khan MA; Aseeri MA; Alshamrani MA; Alnatsheh AH; Alhamdan HS
Glob J Qual Saf Healthc; 2020 Feb; 3(1):22-29. PubMed ID: 37440966
[TBL] [Abstract][Full Text] [Related]
29. "Biosimilar, so it looks alike, but what does it mean?" A qualitative study of Danish patients' perceptions of biosimilars.
Varma M; Almarsdóttir AB; Druedahl LC
Basic Clin Pharmacol Toxicol; 2022 May; 130(5):581-591. PubMed ID: 35261174
[TBL] [Abstract][Full Text] [Related]
30. European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):783-796. PubMed ID: 33141421
[TBL] [Abstract][Full Text] [Related]
31. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper.
Fiorino G; Girolomoni G; Lapadula G; Orlando A; Danese S; Olivieri I;
Autoimmun Rev; 2014 Jul; 13(7):751-5. PubMed ID: 24657898
[TBL] [Abstract][Full Text] [Related]
32. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
[TBL] [Abstract][Full Text] [Related]
33. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
Gecse KB; Cumming F; D'Haens G
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
[TBL] [Abstract][Full Text] [Related]
34. An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review.
Hariprasad SM; Gale RP; Weng CY; Ebbers HC; Rezk MF; Tadayoni R
Ophthalmol Ther; 2022 Jun; 11(3):959-982. PubMed ID: 35278204
[TBL] [Abstract][Full Text] [Related]
35. Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases.
Edwards CJ; Hercogová J; Albrand H; Amiot A
Expert Opin Biol Ther; 2019 Oct; 19(10):1001-1014. PubMed ID: 31056970
[No Abstract] [Full Text] [Related]
36. Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease.
Bhat S; Limdi JK; Cross RK; Farraye FA
Dig Dis Sci; 2021 Aug; 66(8):2513-2532. PubMed ID: 34176024
[TBL] [Abstract][Full Text] [Related]
37. Biosimilars in Oncology in the United States: A Review.
Nabhan C; Parsad S; Mato AR; Feinberg BA
JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
[TBL] [Abstract][Full Text] [Related]
38. Progress with infliximab biosimilars for inflammatory bowel disease.
Kurti Z; Gonczi L; Lakatos PL
Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
[TBL] [Abstract][Full Text] [Related]
39. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis.
Aladul MI; Fitzpatrick RW; Chapman SR
Res Social Adm Pharm; 2019 Mar; 15(3):310-317. PubMed ID: 29807834
[TBL] [Abstract][Full Text] [Related]
40. Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
Araújo FC; Gonçalves J; Fonseca JE
Curr Rheumatol Rep; 2016 Aug; 18(8):50. PubMed ID: 27402107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
